Because mutations in other NF-κB pathway genes, including BIRC3, TRAF2, TRAF3, MAP3K14 and CARD11, have been associated with ibrutinib resistance in mantle cell lymphoma [30, 31], we next investigated whether mutations in NFKBIE could also affect the response to ibrutinib treatment. Here, MAP3K14 is linked to mantle cell lymphoma.